Loading...
OTCM
SSMXY
Market cap5.85bUSD
Dec 05, Last price  
9.23USD
1D
-2.72%
1Q
-29.65%
Jan 2017
-68.17%
Name

Sysmex Corp

Chart & Performance

D1W1MN
OTCM:SSMXY chart
P/E
16.66
P/S
1.76
EPS
86.07
Div Yield, %
Shrs. gr., 5y
8.34%
Rev. gr., 5y
10.99%
Revenues
508.64b
+10.21%
87,887,000,000101,041,000,000110,724,000,000111,842,000,000116,174,000,000124,694,000,000134,743,000,000145,577,000,000184,538,000,000221,376,000,000253,157,000,000249,899,000,000281,935,000,000293,506,000,000301,980,000,000305,073,000,000363,780,000,000410,502,000,000461,510,000,000508,643,000,000
Net income
53.67b
+8.12%
7,422,000,0009,008,000,0009,131,000,0008,013,000,0009,764,000,00011,411,000,00012,007,000,00014,165,000,00020,573,000,00026,638,000,00036,233,000,00040,635,000,00039,221,000,00041,224,000,00034,882,000,00033,142,000,00044,092,000,00045,784,000,00049,639,000,00053,669,000,000
CFO
88.25b
+38.09%
8,275,000,00010,085,000,00011,634,000,00013,193,000,00021,229,000,00018,135,000,00017,058,000,00025,806,000,00036,563,000,00038,640,000,00039,567,000,00032,832,000,00052,240,000,00044,743,000,00053,182,000,00058,813,000,00058,739,000,00068,835,000,00063,905,000,00088,246,000,000
Dividend
Sep 28, 20230.3214 USD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Sysmex Corporation engages in the development, manufacture, and sale of diagnostic instruments, reagents, and related software in Japan. It offers three-part and five-part white blood cell differentiation instruments for use in hematology; and transport systems for high-volume testing in labs. The company also provides automated urine particle analyzers; automated blood coagulation analyzers; automated immunochemistry systems, which perform assays on minute sample quantities, as well as reagents to test for infectious disease and tumor markers; and flow cytometers to perform analysis in diagnosing leukemia, malignant lymphoma, and HIV/AIDS. In addition, it offers cancer lymph node metastasis testing systems to detect information to help in diagnosing lymph node metastasis; and lab assay services. Further, the company is involved in the development and sale of software for diagnostic information systems; provision of facility management, office, welfare, and genetic analysis services; development, operation, and maintenance of IT solutions, platforms, and applications related to digital medicine; marketing, development, design, manufacture, sale, and after-sales service related to medical robots; and distribution and after sales support of medical devices and reagents for biotechnology, medical technology, and molecular cell analysis. Additionally, it researches, develops, manufactures, and sells regenerative medicine products; develops, manufactures, and sells biodevices; develops, maintains, and sells computer software; and offers blood DNA testing service. The company serves national and other public hospitals, private hospitals, universities, research institutes, other medical institutions, etc. It also exports its products to approximately 190 countries. The company was formerly known as TOA Medical Electronics Co., Ltd. and changed its name to Sysmex Corporation in October 1998. Sysmex Corporation was founded in 1968 and is headquartered in Kobe, Japan.
IPO date
Nov 15, 1995
Employees
9,500
Domiciled in
JP
Incorporated in
JP

Valuation

Title
JPY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑032024‑032023‑032022‑032021‑032020‑032019‑032018‑032017‑032016‑03
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT